Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients [PDF]
BMC Medicine, 2022 Background In view of accumulating case reports of thyroid dysfunction following COVID-19 vaccination, we evaluated the risks of incident thyroid dysfunction following inactivated (CoronaVac) and mRNA (BNT162b2) COVID-19 vaccines using a population-based
Carlos King Ho Wong +14 more
doaj +2 more sources
Vaccines, 2023 (1) Background: This study aimed to compare the immunogenicity of the mix-and-match CoronaVac/BNT162b2 vaccination to the homologous CoronaVac/CoronaVac regimen.
Samar Samoud +21 more
doaj +3 more sources
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong [PDF]
EBioMedicine, 2022 Summary: Background: Nearly 4 billion doses of the BNT162b2-mRNA and CoronaVac-inactivated vaccines have been administrated globally, yet different vaccine-induced immunity against SARS-CoV-2 variants of concern (VOCs) remain incompletely investigated ...
Qiaoli Peng +12 more
doaj +3 more sources
Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
Human Vaccines & Immunotherapeutics, 2022 The CoronaVac vaccine was found to be effective against symptomatic COVID-19 and protective against severe disease in phase 3 studies. However, there are little data about its effectiveness in real-world conditions.
Gulsum Iclal Bayhan, Rahmet Guner
doaj +4 more sources
Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study [PDF]
Journal of Hematology & Oncology, 2022 Background The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patients with cancer contributing to ...
Wei Kang +12 more
doaj +2 more sources
Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
Scientific Reports, 2022 Several vaccines have been fast-tracked through clinical trials to mitigate the progression of the SARS‑CoV‑2 pandemic. We analyzed sequential blood samples from 314 recipients of Comirnaty and CoronaVac in East Malaysia for the spike-binding IgG (IgG-S),
Cheng Siang Tan +15 more
doaj +4 more sources
Immunogenicity after CoronaVac vaccination [PDF]
Revista da Associação Médica Brasileira, 2021 This study aimed to investigate the seropositivity of CoronaVac-SinoVac vaccination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) risk factors and comorbidities.Immunoglobulin (IgG) antibody responses were examined on the 21st day after the second dose of CoronaVac-SinoVac 6 μg vaccine on the 28th day.
Eda Çelik Güzel +3 more
openaire +5 more sources
Neutralization of Wild-Type and Alpha SARS-CoV-2 Variant by CoronaVac® Vaccine and Natural Infection- Induced Antibodies [PDF]
, 2023 One of the immune responses desired to be achieved by SARS-CoV-2 vaccination is to create neutralizing antibodies (nAbs), thus preventing the development and spread of infection.
Esra Özkaya +8 more
openalex +4 more sources
Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study [PDF]
, 2022 Objectives In this study covering all of Turkey, we aimed to define cutaneous and systemic adverse reactions in our patient population after COVID-19 vaccination with the Sinovac/CoronaVac (inactivated SARS-CoV-2) and Pfizer/BioNTech (BNT162b2) vaccines.
Aktaş, Nurhan Döner +6 more
core +2 more sources
Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer [PDF]
, 2022 BACKGROUND: Patients with cancer receiving an active systemic therapy are at a high risk for coronavirus disease (COVID-19); however, the antibody response and long-term results of the inactivated whole-virion SARS-CoV-2 (CoronaVac) vaccine in these ...
Eyyüp, Çavdar +6 more
core +1 more source